UK Selects BerGenBio’s Cancer Drug as First Candidate for National COVID-19 Trial

BerGenBio’s investigational cancer treatment bemcentinib was selected as the first potential COVID-19 treatment for a phase 2 study through the UK’s Accelerating COVID-19 Research & Development (ACCORD) platform.

ACCORD’s objective is to rapidly move promising drugs through early stage trials into the UK’s large-scale COVID-19 studies.

BerGenBio will provide the compound and resources for the phase 2 trial. The company anticipates that the first results will be available within a few months.